PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma
BackgroundProgrammed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant pleural mesothelioma (MPM) remains unclear. Evidence suggests that higher PD-L1 expression is correlated with worse survival. CALGB is the main scoring system used...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1269029/full |
| _version_ | 1797405513413033984 |
|---|---|
| author | Alejandro Avilés-Salas Luis Cabrera-Miranda Norma Hernández-Pedro Diana Sofía Vargas-Lías Suraj Samtani Wendy Muñoz-Montaño Daniel Motola-Kuba Luis Corrales-Rodríguez Claudio Martín Andrés F. Cardona Andrés F. Cardona Andrés F. Cardona Cittim B. Palomares-Palomares Oscar Arrieta |
| author_facet | Alejandro Avilés-Salas Luis Cabrera-Miranda Norma Hernández-Pedro Diana Sofía Vargas-Lías Suraj Samtani Wendy Muñoz-Montaño Daniel Motola-Kuba Luis Corrales-Rodríguez Claudio Martín Andrés F. Cardona Andrés F. Cardona Andrés F. Cardona Cittim B. Palomares-Palomares Oscar Arrieta |
| author_sort | Alejandro Avilés-Salas |
| collection | DOAJ |
| description | BackgroundProgrammed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant pleural mesothelioma (MPM) remains unclear. Evidence suggests that higher PD-L1 expression is correlated with worse survival. CALGB is the main scoring system used to predict the benefit of chemotherapy treatment. This study aimed to determine the prognostic value of PD-L1 expression and its addition to CALGB scoring system in patients with MPM.MethodsIn this retrospective analysis, we evaluated samples with confirmed locally advanced or metastatic MPM. PD-L1 Tumor Proportional Score (TPS) was determined by immunohistochemistry at diagnosis.Results73 patients were included in this study. A cutoff value of 15 was set for a high or low PD-L1 TPS. In total, 71.2% (n=52) and 28.8% (n=21) of individuals harbored low or high PD-L1 expression, respectively. PD-L1High was associated with worse median progression-free Survival (mPFS) [4.9 vs. 10.8 months; HR 2.724, 95% CI (1.44-5.14); p = 0.002] and Overall Survival (OS) [6.0 vs. 20.9 months; HR 6.87, 95% CI (3.4-8.7); p<0.001] compared to patients with PD-L1Low. Multivariate analysis confirmed that PD-L1 expression was an independent factor for PFS and OS in patients with MPM and CALGB score of 5-6.ConclusionPD-L1 addition to CALGB scale improves its prognostic estimation of MPM survival and should be considered in future research. |
| first_indexed | 2024-03-09T03:11:06Z |
| format | Article |
| id | doaj.art-8c55a8d1b8f84fa4aee228acd9b565c9 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-09T03:11:06Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8c55a8d1b8f84fa4aee228acd9b565c92023-12-04T04:54:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-12-011310.3389/fonc.2023.12690291269029PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesotheliomaAlejandro Avilés-Salas0Luis Cabrera-Miranda1Norma Hernández-Pedro2Diana Sofía Vargas-Lías3Suraj Samtani4Wendy Muñoz-Montaño5Daniel Motola-Kuba6Luis Corrales-Rodríguez7Claudio Martín8Andrés F. Cardona9Andrés F. Cardona10Andrés F. Cardona11Cittim B. Palomares-Palomares12Oscar Arrieta13Pathology Department, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoPersonalized Medicine Laboratory, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoPathology Department, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoMedical Oncology Department, Clínica Las Condes Santiago, Santiago, ChileThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoDepartments of Biomedical Research and Gastroenterology and Liver Unit and Hemodialysis Unit, Medica Sur Clinic and Foundation, Mexico City, MexicoMedical Oncology Department, San Juan de Dios Hospital, San José, Costa RicaDepartment of Medicine, Western University, London, ON, CanadaThoracic Oncology Unit and Direction of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, ColombiaClinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia0Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, ColombiaThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoBackgroundProgrammed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant pleural mesothelioma (MPM) remains unclear. Evidence suggests that higher PD-L1 expression is correlated with worse survival. CALGB is the main scoring system used to predict the benefit of chemotherapy treatment. This study aimed to determine the prognostic value of PD-L1 expression and its addition to CALGB scoring system in patients with MPM.MethodsIn this retrospective analysis, we evaluated samples with confirmed locally advanced or metastatic MPM. PD-L1 Tumor Proportional Score (TPS) was determined by immunohistochemistry at diagnosis.Results73 patients were included in this study. A cutoff value of 15 was set for a high or low PD-L1 TPS. In total, 71.2% (n=52) and 28.8% (n=21) of individuals harbored low or high PD-L1 expression, respectively. PD-L1High was associated with worse median progression-free Survival (mPFS) [4.9 vs. 10.8 months; HR 2.724, 95% CI (1.44-5.14); p = 0.002] and Overall Survival (OS) [6.0 vs. 20.9 months; HR 6.87, 95% CI (3.4-8.7); p<0.001] compared to patients with PD-L1Low. Multivariate analysis confirmed that PD-L1 expression was an independent factor for PFS and OS in patients with MPM and CALGB score of 5-6.ConclusionPD-L1 addition to CALGB scale improves its prognostic estimation of MPM survival and should be considered in future research.https://www.frontiersin.org/articles/10.3389/fonc.2023.1269029/fullPD-L1CALGBmesotheliomaprognostic factorimmunohistochemistry |
| spellingShingle | Alejandro Avilés-Salas Luis Cabrera-Miranda Norma Hernández-Pedro Diana Sofía Vargas-Lías Suraj Samtani Wendy Muñoz-Montaño Daniel Motola-Kuba Luis Corrales-Rodríguez Claudio Martín Andrés F. Cardona Andrés F. Cardona Andrés F. Cardona Cittim B. Palomares-Palomares Oscar Arrieta PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma Frontiers in Oncology PD-L1 CALGB mesothelioma prognostic factor immunohistochemistry |
| title | PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma |
| title_full | PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma |
| title_fullStr | PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma |
| title_full_unstemmed | PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma |
| title_short | PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma |
| title_sort | pd l1 expression complements calgb prognostic scoring system in malignant pleural mesothelioma |
| topic | PD-L1 CALGB mesothelioma prognostic factor immunohistochemistry |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1269029/full |
| work_keys_str_mv | AT alejandroavilessalas pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT luiscabreramiranda pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT normahernandezpedro pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT dianasofiavargaslias pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT surajsamtani pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT wendymunozmontano pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT danielmotolakuba pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT luiscorralesrodriguez pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT claudiomartin pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT andresfcardona pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT andresfcardona pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT andresfcardona pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT cittimbpalomarespalomares pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma AT oscararrieta pdl1expressioncomplementscalgbprognosticscoringsysteminmalignantpleuralmesothelioma |